Japan approves Gilead Sciences’ remdesivir as COVID-19 drug

FILE PHOTO: A lab technician visually inspects a filled vial of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, U.S. March 11, 2020. Picture taken March 11, 2020. Gilead Sciences Inc/Handout via REUTERS.

TOKYO (Reuters) – Japan has approved Gilead Sciences Inc’s remdesivir as a treatment for COVID-19, the health ministry said on Thursday, making it the country’s first officially authorised drug for the disease.

Japan reached the decision just three days after the U.S. drugmaker had filed for approval.

Remdesivir was granted authorisation last week by the U.S. Food and Drug Administration for emergency use for the disease caused by the coronavirus.

Reporting by Kiyoshi Takenaka

Our Standards:The Thomson Reuters Trust Principles.

Source: http://feeds.reuters.com/~r/Reuters/worldNews/~3/wLzr_tZUky0/japan-approves-gilead-sciences-remdesivir-as-covid-19-drug-idUSKBN22J1UZ